Prospective Cohort Study of Rapid Response Team
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yeon Joo Lee, MD
- Email: yjlee1117@snubh.org
Study Locations
-
-
-
Seongnam-si, Korea, Republic of
- Recruiting
- Seoul National University Bundang Hospital
-
Contact:
- Yeon Joo Lee, MD
- Phone Number: +82317877082
- Email: yjlee1117@snubh.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients admitted to general ward in Seoul National University Bundang Hospital and monitored by in-hospital rapid response system.
Exclusion Criteria:
- patients admitted to pediatric wards
- patients in emergency room, intensive care unit, and operating room
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
mortality or ICU admission of rapid response team activated patient
Time Frame: an average of 1 year
|
an average of 1 year
|
|
incidence of preventable cardiac arrest
Time Frame: an average of 1 year
|
an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of triggerring criteria(1) for activation of rapid response team
Time Frame: an average of 1 year
|
SBP <90mmHg(mABP 60mmHg) +- clinically correlated symptom or sign
|
an average of 1 year
|
|
Frequency of triggerring criteria(2) for activation of rapid response team
Time Frame: an average of 1 year
|
HR: <50/min or >140/min or symptomatic arrythmia
|
an average of 1 year
|
|
Frequency of triggerring criteria(3) for activation of rapid response team
Time Frame: an average of 1 year
|
RR: <10/min or >30/min or stridor(sign of airway obstruction) or accessary muscle use
|
an average of 1 year
|
|
Frequency of triggerring criteria(4) for activation of rapid response team
Time Frame: an average of 1 year
|
Oxygenation: SaO2 <90% in room air or FM 8L/min
|
an average of 1 year
|
|
Frequency of triggerring criteria(5) for activation of rapid response team
Time Frame: an average of 1 year
|
Metabolic acidosis: Lactic acid<2.5 , TCO2 <15
|
an average of 1 year
|
|
Frequency of triggerring criteria(6) for activation of rapid response team
Time Frame: an average of 1 year
|
ABGA abnormality : PaCO2>50 or pH<7.3 or PaO2<60
|
an average of 1 year
|
|
Frequency of triggerring criteria(7) for activation of rapid response team
Time Frame: an average of 1 year
|
ABGA abnormality : PaCO2>50 or pH<7.3 or PaO2<60
|
an average of 1 year
|
|
Frequency of triggerring criteria(8) for activation of rapid response team
Time Frame: an average of 1 year
|
Any serious concern about overall deterioration detected by doctor, nurse and caregiver at bedside
|
an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Yeon Joo Lee, MD, Seoul National University Bundang Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SAFER_20161101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.